Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
Endroit courant :
> This Story

Ouverture ou Registre to rate this News Story
Forward Printable StoryPrint Comment




Molecular Imaging Homepage

Louisiana getting $14 million Center for Molecular Imaging and Therapy Increasing research opportunities, collaboration and radiopharmaceuticals

DOE transfers land to Coquí Pharma for isotope production facility Will be used primarily to produce Mo-99

PET uncovers abnormal tau deposits associated with CTE in live subjects May enable diagnosis of CTE in living people one day

Amyloid PET scans help with Alzheimer's clinical management New insights from the 11,000 patient IDEAS study

United Imaging's total-body PET scanner shows promise in four new studies Faster scans, lower dose and 'a level of detail never seen in PET'

NorthStar buys IBA electron accelerators for Mo-99 production Will increase production capacity and efficiencies

RadioMedix and Vect-Horus to develop brain theranostic agent for brain cancer Provide diagnosis and treatment of Glioblastoma Multiforme (GBM)

NIH awards $1.8 million to Magnetic Insight for neurovascular MPI Detects magnetic nanoparticle tracers, enables deep-tissue imaging

DOE to cut Moly-99 deals with four US firms Could be as much as $15 million per company, with partners matching awarded amounts

Women's brains appear three years younger than men's at the same age: PET study A machine-learning algorithm assisted with the analysis

Zionexa has partnered with Columbia
University's Kreitchman PET Center for the
development and commercialization of
its drug, Estrotep

Zionexa partners with Columbia PET Center on development of EstroTep

par John R. Fischer , Staff Reporter
Columbia University’s Kreitchman PET Center is lending its resources and expertise to radiopharmaceutical provider Zionexa as part of a new partnership overseeing the development and commercialization of its PET diagnostic drug, EstroTep, in the U.S.

Currently only cleared for use in France, the targeted diagnostic biomarker indicates the presence of advanced stage and metastatic breast cancer based on estrogen receptor status in patients.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED

“Image-based biomarker quantitation provides a noninvasive way to personalize cancer therapy,” Akiva Mintz, director of the Columbia University PET Center, said in a statement. “The ability to visualize estrogen receptor expression in all diseased tissue has the potential to change patient management, as cancer is a very heterogeneous disease that is not always accurately evaluated by biopsying a single site of disease, as is the current standard of practice.”

More than 250,000 new cases of breast cancer were reported in 2017 throughout the U.S., making it the most common cancer to affect women.

Zionexa is currently in the process of obtaining clearance for the biomarker, which was on display back in June at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Philadelphia.

With the PET Center, Zionexa will engage in chemistry and method validation research to support the use of its product. “We both have a mission to deliver products that help doctors make better clinical decisions. The work we are doing here with the team at Columbia is helping us to prepare to submit our product to the FDA for evaluation, and hopefully a future commercial launch in the USA” Peter Webner, CEO of Zionexa US, said in a statement.

The partnership is a first for Zionexa, which launched earlier this year under Denos Health Management, the former primary stakeholder of PET diagnostics manufacturer Cyclopharma France and U.S. The company is the former U.S. division of Cyclopharma and was established following the sale of Cyclopharma to Curium.

As part of the acquisition agreement, Denos Health Management purchased the rights to the pipeline of Cyclopharma France, including EstroTep, the first of a number of products to be submitted to the FDA by Zionexa.

Molecular Imaging Homepage

You Must Be Logged In To Post A Comment

Développez la notoriété de votre marque
Enchères + Ventes Privées
Obtenir le meilleur prix
Acheter des équipement / pièces
Trouver le meilleur prix
Infos du jour
Lire Les dernières nouvelles
Consulter tous les utilisateurs DOTmed
Éthique concernant DOTmed
Voir notre programme d'éthique
L'or partie le programme de fournisseur
Recevoir des demandes PH
Programme de marchand de service d'or
Recevoir des demandes
Fournisseurs de soins de santé
Voir tous les outils des HCP (abréviation pour les professionnels de la santé)
Les travaux/Formation
Trouver / combler un poste
Parts Hunter +EasyPay
Obtenir des devis de pièces
Certification Récentes
Voir les utilisateurs récemment certifiés
Evaluation Récentes
Voir les utilisateurs récemment certifiés
Central de location
Louer de l’équipement à moindre prix
Vendre des équipements / pièces
Obtenir le maximum d'argent
Service le forum de techniciens
Trouver de l'aide et des conseils
Simple demande de propositions
Obtenir des devis pour des appareils
Expo Virtuelle
Trouver des services d'appareils
L'Access et l'utilisation de cet emplacement est sujet aux modalités et aux conditions du notre de nos MENTIONS LEGALES & DONNEES PERSONELLES
Propriété de et classe des propriétaires DOTmedà .com, inc. Copyright ©2001-2019 DOTmed.com, Inc.